Effect of recombinant human erythropoietin on vascular access

The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ASAIO transactions 1991-07, Vol.37 (3), p.M274-M275
Hauptverfasser:	DY, G. R, BLOOM, E. J, IEJLU, G. K, MERRITTS, G. W, KRAMER, M. S, RAJA, R. M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Arteriovenous Shunt, Surgical Biological and medical sciences Blood Vessel Prosthesis Blood. Blood coagulation. Reticuloendothelial system Dose-Response Relationship, Drug Erythropoietin - administration & dosage Female Graft Occlusion, Vascular - blood Graft Occlusion, Vascular - chemically induced Hematocrit Humans Kidney Failure, Chronic - blood Kidney Failure, Chronic - therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Polytetrafluoroethylene Recombinant Proteins - administration & dosage Renal Dialysis Retrospective Studies Risk Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The use of recombinant human erythropoietin (r-HuEPO) corrects the anemia of chronic hemodialysis (HD) patients and improves their quality of life. The role of r-HuEPO in the genesis of graft thrombosis is controversial. A retrospective study was conducted of 46 stable chronic HD patients receiving r-HuEPO. It showed an increase in graft thrombosis in those who received the drug.
ISSN:	0889-7190 2375-0952